CRISPR-based genome editing has accelerated biological research and holds great potential for studying and treating human diseases. The CRISPR-Cas9 system requires a Cas9 nuclease and a guide RNA, which may consist of either a CRISPR RNA (crRNA) coupled with a trans-activating crRNA (tracrRNA), or a single guide RNA (sgRNA) that combines the crRNA and tracrRNA in a single molecule. Both guide RNA formats can be chemically synthesized, offering advantages over expression systems. This webinar, sponsored by Horizon Discovery, will explain how synthetic guide RNAs are amenable to chemical modifications for increased stability, eliminate time-consuming steps of cloning and sequencing, and do not provoke the inherent immune response and cytotoxicity of in vitro transcribed guide RNAs. They can be readily delivered into cells for high-throughput arrayed screening applications and expand the types of phenotypic readouts to high-content and morphology-based assays.
Topics to be Covered
The development and application of Horizon Edit-R Synthetic sgRNA reagents for gene specific CRISPR knockout
The functionality and performance of synthetic guide RNAs in several different cell models, including primary T cells
How synthetic guide RNAs provide robust functional gene knockout and further simplify high-throughput loss-of-function screening
Thursday, May 21, 2020
2:30 - 4:00 PM, Eastern Standard Time
Speakers
Kurt Marshall, PhD R&D Scientist Horizon Discovery
Register Now
Leveraging Advances in Predesigned Synthetic sgRNAs for Highly Functional and Specific CRISPR-Cas9 Gene Knockout
You must have Javascript and Cookies enabled to access this webcast.
Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this webinar. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.
